他汀类药物与特发性静脉血栓栓塞症的风险
Statins and the risk of idiopathic venous thromboembolism.
作者信息
Yang Chen-Chang, Jick Susan S, Jick Hershel
机构信息
Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
出版信息
Br J Clin Pharmacol. 2002 Jan;53(1):101-5. doi: 10.1046/j.0306-5251.2001.01523.x.
Abstract
AIMS
To evaluate the association between current statin use and the risk of idiopathic venous thromboembolism (VTE).
METHODS
A population-based retrospective follow-up with a nested case-control analysis using the General Practice Research Database.
RESULTS
There were 72 cases of idiopathic VTE. Using normolipidaemic nonuse as the reference group, the adjusted relative risks for idiopathic VTE for current/recent statin use, past statin use, past other lipid-lowering drug use, and hyperlipidaemic nonuse were 0.8 (0.3, 2.7), 2.4 (0.6, 10.0), 1.8 (0.4, 7.4), and 0.9 (0.4, 2.0) in the follow-up analysis, and were 1.1 (0.3, 4.3), 3.7 (0.6, 24.1), 2.0 (0.3, 11.6), and 0.4 (0.2, 1.2) in the case-control analysis.
CONCLUSIONS
Current statin use was not associated with a reduced risk of idiopathic VTE.
摘要
目的
评估当前使用他汀类药物与特发性静脉血栓栓塞症（VTE）风险之间的关联。
方法
基于人群的回顾性随访，并使用全科医学研究数据库进行巢式病例对照分析。
结果
有72例特发性VTE病例。在随访分析中，以血脂正常未使用者作为参照组，当前/近期使用他汀类药物、过去使用他汀类药物、过去使用其他降脂药物以及血脂异常未使用者发生特发性VTE的校正相对风险分别为0.8（0.3，2.7）、2.4（0.6，10.0）、1.8（0.4，7.4）和0.9（0.4，2.0）；在病例对照分析中，上述风险分别为1.1（0.3，4.3）、3.7（0.6，24.1）、2.0（0.3，11.6）和0.4（0.2，1.2）。
结论
当前使用他汀类药物与特发性VTE风险降低无关。
相似文献
1
Statins and the risk of idiopathic venous thromboembolism.
Br J Clin Pharmacol. 2002 Jan;53(1):101-5. doi: 10.1046/j.0306-5251.2001.01523.x.
2
Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study.
Thromb Res. 2015 Jun;135(6):1110-6. doi: 10.1016/j.thromres.2015.04.005. Epub 2015 Apr 11.
3
Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study.
Fundam Clin Pharmacol. 2004 Aug;18(4):477-82. doi: 10.1111/j.1472-8206.2004.00252.x.
4
Statin use and risk of first-time psoriasis diagnosis.
J Am Acad Dermatol. 2011 Jul;65(1):77-83. doi: 10.1016/j.jaad.2010.05.039. Epub 2011 May 6.
5
Statins decrease the occurrence of venous thromboembolism in patients with cancer.
Am J Med. 2010 Jan;123(1):60-5. doi: 10.1016/j.amjmed.2009.05.025.
6
HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis.
J Thromb Haemost. 2009 Apr;7(4):514-20. doi: 10.1111/j.1538-7836.2008.03235.x. Epub 2008 Nov 24.
7
The association of statin therapy with the risk of recurrent venous thrombosis.
J Thromb Haemost. 2016 Jul;14(7):1384-92. doi: 10.1111/jth.13334. Epub 2016 Jun 20.
8
Lipid lowering drugs and the risk of recurrent venous thromboembolism.
Thromb Res. 2012 Dec;130(6):859-63. doi: 10.1016/j.thromres.2012.08.296. Epub 2012 Aug 30.
9
Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis.
Ann Rheum Dis. 2009 Apr;68(4):546-51. doi: 10.1136/ard.2008.091967. Epub 2008 Jul 28.
10
Statin Use is Associated with Reduced Risk of Recurrence in Patients with Venous Thromboembolism.
Am J Med. 2020 Aug;133(8):930-935.e8. doi: 10.1016/j.amjmed.2019.12.032. Epub 2020 Mar 12.
引用本文的文献
1
Statins for the primary prevention of venous thromboembolism.
Cochrane Database Syst Rev. 2024 Nov 5;11(11):CD014769. doi: 10.1002/14651858.CD014769.pub2.
2
Risk of Venous Thromboembolism in Statin Users Compared to Fibrate Users in the United Kingdom Clinical Practice Research Datalink (UK CPRD) GOLD.
Clin Epidemiol. 2024 Oct 5;16:683-697. doi: 10.2147/CLEP.S481448. eCollection 2024.
3
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024;22(4):297-300. doi: 10.2174/0115701611308323240229050237.
4
Risk of Venous Thromboembolism with Statins: Evidence Gathered via a Network Meta-analysis.
Balkan Med J. 2023 Sep 11;40(5):324-332. doi: 10.4274/balkanmedj.galenos.2023.2023-5-26. Epub 2023 Jul 31.
5
Statins can benefit patients with primary membranous nephropathy on venous thromboembolism.
Ren Fail. 2021 Dec;43(1):302-306. doi: 10.1080/0886022X.2021.1879853.
6
How to validate a diagnosis recorded in electronic health records.
Breathe (Sheff). 2019 Mar;15(1):64-68. doi: 10.1183/20734735.0344-2018.
7
Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study.
Thromb Res. 2015 Jun;135(6):1110-6. doi: 10.1016/j.thromres.2015.04.005. Epub 2015 Apr 11.
8
Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy.
Thromb J. 2014 Nov 26;12:26. doi: 10.1186/1477-9560-12-26. eCollection 2014.
9
Statins for primary prevention of venous thromboembolism.
Cochrane Database Syst Rev. 2014 Dec 18;2014(12):CD008203. doi: 10.1002/14651858.CD008203.pub3.
10
Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis.
BMC Med. 2014 Mar 22;12:51. doi: 10.1186/1741-7015-12-51.
本文引用的文献
1
Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis.
BMJ. 2000 Nov 11;321(7270):1190-5. doi: 10.1136/bmj.321.7270.1190.
2
Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study.
Ann Intern Med. 2000 May 2;132(9):689-96. doi: 10.7326/0003-4819-132-9-200005020-00002.
3
Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.
JAMA. 1999;282(24):2340-6. doi: 10.1001/jama.282.24.2340.
4
Hemostatic effects of smoking and oral contraceptive use.
Am J Obstet Gynecol. 1999 Jun;180(6 Pt 2):S369-74. doi: 10.1016/s0002-9378(99)70698-8.
5
The risk of venous thromboembolism in users of postcoital contraceptive pills.
Contraception. 1999 Feb;59(2):79-83. doi: 10.1016/s0010-7824(99)00011-6.
6
Tamoxifen and risk of idiopathic venous thromboembolism.
Br J Clin Pharmacol. 1998 Jun;45(6):608-12. doi: 10.1046/j.1365-2125.1998.00733.x.
7
Hormone replacement therapy and risk of venous thromboembolism: population based case-control study.
BMJ. 1997 Mar 15;314(7083):796-800. doi: 10.1136/bmj.314.7083.796.
8
Risk of venous thromboembolism in users of hormone replacement therapy.
Lancet. 1996 Oct 12;348(9033):977-80. doi: 10.1016/S0140-6736(96)07113-9.
9
National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
Circulation. 1994 Mar;89(3):1333-445. doi: 10.1161/01.cir.89.3.1333.
10
Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
Lancet. 1995 Dec 16;346(8990):1589-93. doi: 10.1016/s0140-6736(95)91928-7.
Zotero 插件